Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies by Motokura, Toru et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Aberrant overexpression of an epithelial marker, 14-3-3σ, in a 
subset of hematological malignancies
Toru Motokura*, Yukari Nakamura and Hiroyuki Sato
Address: Department of Hematology and Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
Email: Toru Motokura* - motokura@grape.med.tottori-u.ac.jp; Yukari Nakamura - ynakamura-tky@umin.ac.jp; Hiroyuki Sato - satouhi1-
tky@umin.ac.jp
* Corresponding author    
Abstract
Background: 14-3-3σ is a p53-mediated cell-cycle inhibitor in epithelial cells. The expression of
14-3-3σ is frequently altered in cancers of epithelial origin associated with altered DNA
methylation. Since its involvement in a non-epithelial tumor is unknown, we examined 14-3-3σ
expression in patients with haematological malignancies.
Methods: We analyzed 41 hematopoietic cell lines and 129 patients with a variety of hematological
malignancies for 14-3-3σ expression with real-time RT-PCR. We also examined protein levels by
Western blot analysis and DNA methylation status of the 14-3-3σ gene by methylation-specific
PCR analysis of bisulfite-treated DNA. In addition, mutations of p53 gene were identified by RT-
PCR-SSCP analysis and the expression levels of 14-3-3σ were compared with those of other cell-
cycle inhibitor genes, CDKN2A and ARF.
Results: The expression levels of 14-3-3σ mRNA in almost all cell lines were low and comparable
to those in normal hematopoietic cells except for 2 B-cell lines. On the contrary, 14-3-3σ mRNA
was aberrantly overexpressed frequently in mature lymphoid malignancies (30 of 93, 32.3%) and
rarely in acute leukemia (3 of 35, 8.6%). 14-3-3σ protein was readily detectable and roughly
reflected the mRNA level. In contrast to epithelial tumors, methylation status of the 14-3-3σ gene
was not associated with expression in hematological malignancies. Mutations of p53 were identified
in 12 patients and associated with lower expression of 14-3-3σ. The expression levels of 14-3-3σ,
CDKN2A and ARF were not correlated with but rather reciprocal to one another, suggesting that
simultaneous overexpression of any two of them is incompatible with tumor growth.
Conclusion: 14-3-3σ, an epithelial cell marker, was overexpressed significantly in a subset of
mature lymphoid malignancies. This is the first report of aberrant 14-3-3σ expression in non-
epithelial tumors in vivo. Since the significance of 14-3-3σ overexpression is unknown even in
epithelial tumors such as pancreatic cancers, further analysis of regulation and function of the 14-
3-3σ gene in non-epithelial as well as epithelial tumors is warranted.
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Background
14-3-3 proteins regulate many cellular processes such as
cell motility, growth, differentiation, apoptosis and cell-
cycle checkpoints [1,2] and are involved in tumorigenesis.
Among seven members of the 14-3-3 gene family, 14-3-3σ
is the most frequently implicated in cancer development
[3] and is a mediator of p53 tumor suppressor to arrest
cell cycle at the G2 phase by sequestering CDK1/cyclin B
complex in cytoplasm [4,5]. 14-3-3σ, also known as strat-
ifin (SFN), was identified as an epithelial cell marker pro-
tein [6] and was expressed primarily in epidermal
epithelia during keratinocyte differentiation. Knockdown
of 14-3-3σ expression leads to immortalization of pri-
mary human keratinocytes [7]. Furthermore, lack of 14-3-
3σ expression associated with DNA methylation of a CpG
island residing on the gene is frequently observed in many
cancers of epithelial origin such as breast cancers [8,9],
liver cancers [10], oral carcinomas [11], and lung cancers
[12]. In addition to DNA methylation, estrogen-respon-
sive finger protein, Efp, is implicated in 14-3-3σ down-
regulation through proteolysis by its ubiquitin ligase
activity [13].
On the contrary, 14-3-3σ can suppress cell death by bind-
ing to proapoptotic protein, Bax, and thus could function
as an oncoprotein [14]. Consistent with such a possibility,
cDNA microarray analysis of pancreatic carcinomas
revealed that 14-3-3σ is overexpressed as compared to
normal pancreas, which was associated with aberrant
hypomethylation in the majority of pancreatic cancers
analyzed [15]. 14-3-3σ overexpression was found in pap-
illary but not follicular carcinomas of the thyroid [16]. In
addition, increasing 14-3-3σ expression is associated with
malignant progression of endometrial carcinoma [17].
These findings raise a 14-3-3σ paradox [1] and suggest
that 14-3-3σ is not just a cell-cycle inhibitor or a tumor
suppressor but implicated in tumor development as an
oncoprotein through anti-apoptotic function or other
unknown mechanisms.
Recently, we found that 14-3-3σ was up-regulated in non-
epithelial tumor models of rat embryo fibroblasts trans-
formed with c-myc and activated H-ras [18]. Culture con-
ditions greatly affected the expression levels and
methylation status of the 14-3-3σ gene although expres-
sion of any other 14-3-3 family member was not altered at
all (unpublished data). Sparse culture (r-selection)
resulted in decreased 14-3-3σ expression along with DNA
methylation while the gene was overexpressed and
demethylated under a confluent culture condition (K-
selection) [18]. Therefore, 14-3-3σ may play roles in the
development of even non-epithelial tumors either as a
tumor suppressor or oncoprotein dependent upon a selec-
tion modality governing tumor development of each spe-
cific tumor. In addition, non-epithelial astrocytes in the
brain were reported to express 14-3-3σ in response to oxi-
dative and DNA-damaging stresses, suggesting a patho-
logical role of 14-3-3σ in non-epithelial cells [19].
Bahtia et al. reported that 14-3-3σ mRNA is expressed at
low levels in peripheral blood (PB) lymphocytes [20] and
the gene is methylated. In addition, 14-3-3σ protein exists
in PB mononuclear cells (MNC) [20,21]. However, the
significance of 14-3-3σ expression in non-epithelial,
hematological malignancies is unknown. In this study, we
examined 129 patients with hematological malignancies
for 14-3-3σ expression by real-time RT-PCR and found
that aberrant overexpression exists in a subset of patients
with mature lymphoid malignancies. This is the first
report suggesting the involvement of 14-3-3σ in non-epi-
thelial tumors.
Methods
Cell Lines and Clinical Materials
Cell lines and clinical specimens examined in this study
were derived from a collection of our laboratory as previ-
ously described [22,23]. Clinical specimens were largely
from the archived samples obtained for diagnostic pur-
poses and control specimens from healthy volunteers
were obtained with written informed consents. The study
was approved by the institutional review board. All speci-
mens of hematological malignancies had more than 70%
malignant cells as judged with cytosmears.
Real-Time Reverse Transcription (RT)-Polymerase Chain 
Reaction (PCR)
RNA extraction and cDNA synthesis were done as
described [22]. RNA of each cell line was extracted during
log-phase growth. The cDNAs were subjected to real-time
PCR for the human 14-3-3σ and GAPDH genes using Taq-
Man Universal PCR Master Mix (Applied Biosystems, Fos-
ter City, CA) according to the manufacturer's protocol
with an ABI PRISM 7700 Sequence Detector (Applied Bio-
systems). Primers and VIC-TAMRA probe for human 14-
3-3σ and GAPDH were purchased from Applied Biosys-
tems and used at 0.1 µM and 0.2 µM, respectively. Ratios
of the 14-3-3σ to GAPDH values in each sample were
standardized by that obtained with Jurkat cells, which was
very close to the average value of normal tissues.
Western Blot Analysis
Cells and clinical specimens were lyzed with 1 × sample
buffer (Tris-HCl 60 mM, SDS 2%, dithiothreitol 0.1 M,
pH 6.8) and boiled for 5 minutes. Protein concentration
was determined by spectrophotometry using BCA Protein
Assay Reagent (Pierce, Rockford, IL, USA) [24]. Proteins
were separated on a 12% SDS-polyacrylamide gel and
subjected to Western blot analysis as described [25]. Qual-
ity of protein was judged by Ponceau S staining and cases
of degraded proteins were excluded from analysis. Anti-BMC Cancer 2007, 7:217 http://www.biomedcentral.com/1471-2407/7/217
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14-3-3σ monoclonal antibody (CS112-2A8 clone;
Upstate Biotechnology, Lake Placid, NY) and anti-α-tubu-
lin monoclonal antibody (Ab-1; Oncogene Research
Products, San Diego, CA) were used at 1.3 µg/mL and at
0.2 µg/mL, respectively. A secondary antibody was alka-
line phosphatase-conjugated rabbit anti-mouse IgG1 anti-
body (Zymed Laboratories) used at 1:1000 dilution.
Methylation-Specific PCR (MSP) Analysis of Bisulfite-
Treated DNA
Genomic DNA was extracted with a conventional method
and was modified with sodium bisulfite as described [26].
Sodium bisulfite-treated genomic DNA (100 ng) was sub-
jected to PCR reactions using the following primers: 5'-
TGGTAGTTTTTATGAAAGGCGTC-3' and 5'-CCTCTAAC-
CGCCCACCACG-3' for methylated DNA; 5'-ATGG-
TAGTTTTTATGAAAGGTGTT-3' and 5'-
CCCTCTAACCACCCACCACA-3' for unmethylated DNA
[8]. These primer sets assessed 4 CpG dinucleotides span-
ning nucleotides +184–289 (as the first ATG +1, GenBank
accession number AF029081) in the CpG island. PCR
conditions were as described [20].
RT-PCR-single-strand conformation polymorphism (SSCP) 
analysis
The above-mentioned cDNA was subjected to RT-PCR for
p53 DNA binding region (exons 4–9, GenBank accession
number NM000546). The primers were 5'-CTGTCATCT-
TCTGTCCCTTC-3' and 5'-TTTCTTTTGCTGGGGAGAGG-
3' (0.5 µM each) and the conditions were described previ-
ously [27]. After each of two different restriction enzyme
treatments (HpaII and Sau96I/PvuII), SSCP was done
using a non-radioactive method with silver staining as
described [28]. When aberrant signals were obtained,
amplified DNAs were subjected to direct sequencing using
an ABI PRISM BigDye Terminator cycle sequencing Ready
Reaction Kit and ABI PRISM Model 310 auto sequencer
(Applied Biosystems).
Statistical Analysis
Mann-Whitney's U test, Kruskal-Wallis test and Scheffe
test were used for comparison of 14-3-3σ mRNA levels.
Results
Expression of 14-3-3σ mRNA and protein in hematological 
malignancies
We examined 41 hematopoietic cell lines and clinical
specimens of 129 patients with a variety of hematological
malignancies for expression of the 14-3-3σ gene with real-
time RT-PCR. The expression in normal tissues such as
bone marrow (BM) and PB MNC and reactive lymph
nodes were also examined as controls. The expression lev-
els in almost all cell lines examined were detectable but
low and comparable to those in normal tissues. Only in
two B-cell lines, i.e., BALL-1 and LBW2, the expression lev-
els of 14-3-3σ mRNA increased beyond the mean plus 2
standard deviations (SDs) of the controls (mean 1.03, SD
0.57) as shown in Figure 1. Myeloid cell lines expressed
significantly less than lymphoid cell lines (P < 0.0001 by
Kruskall-Wallis test). On the contrary, the expression lev-
els were frequently elevated among the clinical specimens
of patients with a variety of hematological malignancies
and significantly different among the types of diseases (P
= 0.001 by Kruskall-Wallis test). In patients with mature
lymphoid malignancies, increased expression was found
in 30 (32.3%) of 93 patients (chronic lymphocytic leuke-
mia 3/8, diffuse large B-cell lymphoma 9/27, follicular
lymphoma 7/29, adult T-cell leukemia/lymphoma 2/8,
other lymphomas 4/9, plasma cell dyscrasia 5/12)
whereas only 3 (8.6%) of 35 patients with acute leukemia
expressed 14-3-3σ at the increased levels (acute lymphoid
leukemia 1/16, acute myeloid leukemia 2/12, blast crisis
of chronic myeloid leukemia 0/7).
Since 14-3-3σ expression is regulated post-translationally,
we also examined protein levels in 34 patients with mate-
rials available enough to Western blot analysis. The 14-3-
3σ protein is readily detectable and roughly reflected the
mRNA levels (Figure 2). In patients with high mRNA
expression levels comparable to that of a HeLa epithelial
cell line, the protein levels in hematological malignancies
were well below that of HeLa (see one tenth amount of
lysate was loaded for HeLa cells), suggesting the presence
of different regulatory mechanisms between epithelial
and non-epithelial cells.
DNA methylation status of the 14-3-3σ gene is not 
associated with its expression
Since the expression levels and DNA methylation status of
the 14-3-3σ gene is highly related in epithelial tumors, we
examined the methylation status in 21 patients with MSP
analysis of bisulfite-treated DNA. Representative results
are shown in Figure 3. In PBMNC and BMMNC with low
expression of 14-3-3σ mRNA, DNA was not always meth-
ylated and similar results were obtained in patients with
malignancies. A limited number of patients showed
unmethylated status and did not necessarily express high
levels of 14-3-3σ mRNA and vice versa. These results sug-
gest that expression of 14-3-3σ in hematological malig-
nancies is not mainly affected by the DNA methylation
status to the extent observed in epithelial tumors. How-
ever, further study with a larger series of patients is
required to confirm the finding.
Comparison with CDKN2A and ARF expression and 
impact of p53 mutations
14-3-3σ is an effector molecule downstream of p53 tumor
suppressor [4] whereas ARF protein derived from the
CDKN2A/ARF locus functions upstream of p53 [29]. ARF
expression activates p53 and thus can arrest the cell cycleBMC Cancer 2007, 7:217 http://www.biomedcentral.com/1471-2407/7/217
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at the G1 and G2 phases through direct activation of
p21CIP1 and 14-3-3σ, respectively [3,30]. In our previous
study, we had examined the same collection of clinical
specimens for expression of CDKN2A and ARF mRNAs
with β-actin as a control [23] and then we compared the
expression levels of these mRNAs. As shown in Figure 4,
high expression of ARF mRNA was not accompanied by its
downstream event, i.e., induced expression of 14-3-3σ
mRNA. Because of possible presence of p53 mutations
disrupting the signaling pathway from ARF to 14-3-3σ, we
examined these patients with RT-PCR-SSCP analysis to
identify patients with p53 mutations. Twelve mutated
patients were found out of 127 patients examined and dis-
tributed in a variety of malignancies as shown in Figure 1
(see open circles). The mutated patients expressed signifi-
cantly higher levels of ARF mRNA and lower levels of 14-
3-3σ than non-mutated ones (P < 0.05 in either case by
Mann-Whitney's U test, Figure 4). Thus, p53 mutation
appears to disrupt the signaling pathway from ARF to 14-
3-3σ. In normal keratinocytes, 14-3-3σ expression is
accompanied by CDKN2A expression but in hematologi-
cal malignancies 14-3-3σ expression was rarely accompa-
nied by CDKN2A expression. Interestingly, CDKN2A and
ARF expression levels were not correlated either but rather
reciprocal.
Discussion
The 14-3-3σ gene is highly expressed in epithelial cells
and implicated in the development of many cancers of
epithelial origin. In the present study, 14-3-3σ expression
was found at low levels in normal PB and BM MNC and
lymph nodes, consistent with the previous observation by
Expression of 14-3-3σ mRNA in hematological malignancies and cell lines Figure 1
Expression of 14-3-3σ mRNA in hematological malignancies and cell lines. Expression levels of 14-3-3σ mRNA were 
determined by real-time RT-PCR and standardized by that of Jurkat cells (an open square). Dotted line denotes mean plus 2 
SDs (2.17) of controls and a mean for each disease or cell line is shown as a horizontal bar. The vertical scales are different 
between the lower and higher levels. Open circles denote patients with p53 mutations identified by RT-PCR-SSCP analysis. 
Controls include 5 PBMNC, 3 BMMNC, 2 reactive lymph nodes; CML, 7 patients with blast crisis (BC) and 1 patient with 
chronic phase (CP) of chronic myeloid leukemia; AML, 12 patients with acute myeloid leukemia; ALL, 16 patients with acute 
lymphoid leukemia including 3 patients with Burkitt leukemia/lymphoma; ATL, 8 patients with adult T-cell leukemia/lymphoma 
(1 chronic, 1 acute, and 6 lymphoma variants); CLL, 5 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma 
and 3 patients with prolymphocytic leukemia; DLBCL, 27 patients with diffuse large B-cell lymphoma; FL, 29 patients with follic-
ular lymphoma; other NHL, 4 patients with T-cell lymphoma, 2 patients with mantle cell lymphoma and 3 patients with unclas-
sified lymphoma; PCD, 12 patients with plasma cell dyscrasias including 1 patient with plasma cell leukemia, 4 patients with 
Waldenström's macroglobulinemia and 7 patients with multiple myeloma; cell lines include 14 myeloid, 15 T-cell, and 10 B-cell 
lines (all listed in reference [23]) and an epithelial cell line, HeLa (an open triangle). Asterisks denote statistical significance by 
Scheffe test after combining CML BC, AML and ALL as a group of acute leukemia and DLBCL, FL and other NHL as a group of 
NHL: * P < 0.05, ** P < 0.01.BMC Cancer 2007, 7:217 http://www.biomedcentral.com/1471-2407/7/217
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Bahtia et al [20]. We also found that the expression of 14-
3-3σ mRNA and protein increased in a substantial
number of patients with hematological malignancies. The
clinical specimens examined in this study were hardly
contaminated with 14-3-3σ-overexpressing epithelial
cells. There remains a possibility of normal cells admixed
in tumor specimens may upregulate 14-3-3σ expression
although expression by small number of normal cells
should hardly explain the cases of high expression compa-
rable to HeLa cells. The increased expression was not con-
fined to any specific disease but found in a category of
mature lymphoid malignancies. These findings suggest
that the aberrant expression is implicated in the develop-
ment of non-epithelial tumors as well as epithelial can-
cers. However, there remains to investigate whether the
increased expression may reflect normal development of
lymphoid cells.
The 14-3-3σ mRNA levels in almost all cell lines were sup-
pressed whereas those in clinical specimens were highly
variable. Our previous study revealed that r-selection
favored cells with low expression of 14-3-3σ and thus, the
establishment of cell lines may also select clones which
express 14-3-3σ at low levels rather than at high levels.
The bias of cell line establishment has also been debated
regarding other aberrations such as CDKN2A/ARF locus
deletion [31]. During the development of acute leukemia,
r-selection may well be active since leukemia cells can
grow rapidly in general but not localized bone marrow. It
is consistent with the finding that upregulation of 14-3-3σ
was rare in acute leukemia. On the other hand, high-cell-
density selection (K-selection) was associated with 14-3-
3σ overexpression and emergence of multidrug resistance
[18,32]. Furthermore, 14-3-3σ expression contributes to
drug resistance and loss of 14-3-3σ expression sensitizes
cancer cells to anticancer agents [3,33]. The concepts of r-
and K-selection did not constitute a true dichotomy but
merely represent endpoints of a spectrum. Selection
modalities are relative and determined by the interaction
between tumor cells and their microenvironment. There-
fore, K-selection may work during the development of
tumors in vivo especially tumor-forming malignancies and
14-3-3σ overexpression in a subset of patients with
mature lymphoid tumors may reflect the selection proc-
esses that were more K than those in other patients. How-
ever, its prognostic significance remains to be
investigated.
In many epithelial tumors, DNA methylation status is
highly associated with the expression levels of 14-3-3σ.
However, the present observation suggested that
unknown mechanisms other than DNA methylation are
involved in the aberrant expression in hematological
malignancies. In addition, the protein level in HeLa cells
was much higher than those in hematological malignan-
cies even in patients whose mRNA levels were comparable
to that of HeLa cells. The comparison between three cell-
cycle inhibitors, 14-3-3σ, ARF, and CDKN2A, suggested
that their associated expressions found in normal epithe-
lial cells were lacking. The disrupted link between ARF
and 14-3-3σ may well be explained at least in part by the
presence of p53 mutations. However, these comparisons
were made between data obtained by different methods
with a small number of p53-mutated cases. Therefore,
14-3-3σ protein expression in hematological malignancies Figure 2
14-3-3σ protein expression in hematological malignancies. Western blot analysis of whole lysates (20 µg/lane) of clini-
cal specimens of hematological malignancies was done with anti-14-3-3σ monoclonal antibody. A representative result is 
shown with HeLa cells (2 µg/lane) as a control. Anti-α-tubulin antibody was used to show the protein loading. 14-3-3σ mRNA 
expression levels determined by real-time RT-PCR and standardized to that of Jurkat cells are shown below.BMC Cancer 2007, 7:217 http://www.biomedcentral.com/1471-2407/7/217
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confirmation with a larger series of patients is required.
Intriguingly, expression levels of any two of them were all
reciprocal. Simultaneous overexpression of any two of
them seem to be incompatible with tumor development
and overexpression of any one of them may indicate that
some parts in the braking systems of these cell-cycle inhib-
itors are broken [34]. However, the regulatory mecha-
nisms and function of 14-3-3σ in non-epithelial cells
remain unknown. Even in epithelial tumors, the function
of 14-3-3σ overexpressed in pancreatic cancers is enig-
matic [35]. The regulation and function of the 14-3-3σ
gene in non-epithelial lymphoid malignancies require
further analysis.
Conclusion
We found that 14-3-3σ, an epithelial cell marker, was
overexpressed significantly in a subset of mature lym-
phoid malignancies in vivo. The expression levels of 14-3-
3σ mRNA were not associated with the DNA methylation
status of the CpG island. These findings warrant further
analysis of regulation and function of the 14-3-3σ gene
even in non-epithelial tumors such as hematological
malignancies.
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MSP analysis of DNA methylation status of the 14-3-3σ gene Figure 3
MSP analysis of DNA methylation status of the 14-3-
3σ gene. Bisulfite-treated genomic DNA was subjected to 
MSP and amplified products were separated on 1.5% agarose 
gel. Representative results are shown. The 14-3-3σ mRNA 
expression levels determined by real-time RT-PCR are 
shown below. M and U denotes methylated and unmethyl-
ated alleles, respectively. PCL denotes plasma cell leukemia; 
MM, multiple myeloma; CML-CP, chronic phase of chronic 
myeloid leukemia; PLL, prolymphocytic leukemia.
Comparison of mRNA expression levels between three cell-cycle inhibitors, 14-3-3σ, ARF and CDKN2A Figure 4
Comparison of mRNA expression levels between three cell-cycle inhibitors, 14-3-3σ, ARF and CDKN2A. ARF 
and CDKN2A mRNA levels were determined by semi-quantitative RT-PCR previously [23]. For each pair of cell-cycle inhibi-
tors, expression levels are plotted in scattered plots. Open circles denote patients with p53 mutations identified by RT-PCR-
SSCP analysis. Correlation coefficients for p53 wild-type and mutated patients are: 14-3-3σ vs. ARF, -0.074 and -0.129; 14-3-3σ 
vs. CDKN2A, -0.033 and -0.391; ARF vs. CDKN2A, -0.044 and -0.177, respectively.BMC Cancer 2007, 7:217 http://www.biomedcentral.com/1471-2407/7/217
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